Fuzheng Xiaoji granules combined with frontline chemotherapy in colorectal cancer patients with stasis and toxin internal obstruction syndrome

doi:10.16138/j.1673-6087.2025.01.02

Abstract

Abstract:

Objective To observe the clinical efficacy of Fuzheng Xiaoji granules combined with first-line chemotherapy in colorectal cancer patients with stasis toxin internal obstruction syndrome and the influence of gut microbiota in them. Methods A total of 100 stage Ⅳ colorectal cancer patients with stasis toxin internal obstruction syndrome admitted to Ruijin Hospital,Shanghai Jiao Tong University School of Medicine from January 1, 2019 to December 31, 2023 were selected as the study subjects. They were randomly divided into a control group and a treatment group using a random number table method, with 50 cases in each group. The control group received standard Western medicine chemotherapy, and the treatment group was given modified oral Fuzheng Xiaoji granules combined with chemotherapy. Six months later, the traditional Chinese medicine syndrome scores and Kanofsky performance score (KPS) of the two groups before, during, and after treatment were compared between the two groups, and the gut microbiota were compared between the two groups. Results Before treatment, the traditional Chinese medicine syndrome scores and KPS of the two groups were similar, and the difference was not statistically significant (both P>0.05). After treatment, the scores of depression, anxiety, and fatigue in the treatment group decreased compared to those before treatment (all P<0.05). Tingling, localized pain, refusal to press, depression and anxiety, and fatigue in the treatment group decreased compared with those in the control group (all P<0.01). The symptoms in the control group were similar, and the difference was not statistically significant (all P>0.05). The results of two groups of gut microbiota showed a slight increase in the abundance of gut microbiota in the control group compared to the treatment group. The differential microbiota with linear discriminant analysis (LDA) values>2 in the two groups were Actinobacteria, Ruminococcus, Clostridium, Campylobacter, Abiotrophya, Chloroplast, and Pseudomonas in the control group, and Aeromonas in the treatment group. Conclusions The combination of Fuzheng Xiaoji granules and first-line chemotherapy can improve the quality of life of colorectal cancer patients with stasis toxin internal obstruction syndrome, regulate the patient's gut microbiota, and improve traditional Chinese medicine symptoms.

Key words: Traditional Chinese medicine, Intestinal microbiota, Stasis and toxin internal obstruction syndrome, Colorectal cancer, Famous traditional Chinese medicine experience

CLC Number:

R735.3

LYU Lingling, XU Yumin, XU Cheng, ZHENG Lan. Fuzheng Xiaoji granules combined with frontline chemotherapy in colorectal cancer patients with stasis and toxin internal obstruction syndrome[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(01): 7-13.

Figures/Tables 9

Table 1

Table 2

Figure 1

Figure 2

Table 3

Figure 3

Figure 4

Figure 5

Figure 6

References 25

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2]	Zhang T, Yang YF, He B, et al. Efficacy and safety of Quxie capsule () in metastatic colorectal cancer: a double-blind randomized placebo controlled trial[J]. Chin J Integr Med, 2018, 24(3):171-177. doi: 10.1007/s11655-017-2962-2 pmid: 28840585
[3]	Ivey GD, Johnston FM, Azad NS, et al. Current surgical management strategies for colorectal cancer liver metastases[J]. Cancers (Basel), 2022, 14(4):1063.
[4]	李延青. 我国现阶段结直肠癌筛查新模式:机会性筛查[J]. 中华医学信息导报, 2020, 35(22):18.
[5]	Czauderna C, Luley K, von Bubnoff N, et al. Tailored systemic therapy for colorectal cancer liver metastases[J]. Int J Mol Sci, 2021, 22(21):11780.
[6]	郑岚, 吕玲玲, 应海峰, 等. 扶中消积分期疗法治疗直肠癌生存分析[J]. 辽宁中医药大学学报, 2018, 20(1):11-14.
[7]	吕玲玲, 陈敬贤, 武渊, 等. 基于真实世界理论的扶中消积法治疗结直肠癌的生存状况分析及预测[J]. 中国中医药科技, 2022, 29(3):401-404.
[8]	王婷, 周利红, 李琦, 等. 肠道菌群对肿瘤的影响及中医药调节作用研究进展[J]. 中华中医药学刊, 2019, 37(11):2704-2707.
[9]	陈慧敏, 房静远. 微生物组学与肠道肿瘤[J]. 生命科学, 2017, 29(7):636-643.
[10]	Jahani-Sherafat S, Alebouyeh M, Moghim S, et al Role of gut microbiota in the pathogenesis of colorectal cancer; a review article[J]. Gastroenterol Hepatol Bed Bench, 2018, 11(2):101-109.
[11]	张影茹, 李琦, 王炎. 肠道菌群失调对结直肠癌的影响及中医药调控机制[J]. 中国现代普通外科进展, 2019, 22(8):669-672.
[12]	国家药品管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社,2002:208-212.
[13]	叶凡, 李琢, 黄兴, 等. 益生菌辅助化疗对晚期大肠癌患者的临床疗效和安全性评价[J]. 中国药师, 2024, 27(2):295-301.
[14]	刘俊希, 王舒, 魏祯, 等. 中药有效成分通过调节肠道菌群及代谢物组成影响相关疾病治疗作用概述[J]. 中医药学报, 2022, 50(2):92-97.
[15]	Shen H, Gao XJ, Li T, et al. Ginseng polysaccharides enhanced ginsenoside Rb1 and microbial metabolites exposure through enhancing intestinal absorption and affecting gut microbial metabolism[J]. J Ethnopharmacol, 2018,216:47-56.
[16]	范奎, 马胜男, 曹芳. 中医药调节肠道菌群对结直肠癌治疗的临床价值[J]. 中医药学报, 2021, 49(3):110-114.
[17]	杨怀勇, 黎麟达. 双歧杆菌三联活菌胶囊联合二甲双胍治疗对结直肠癌合并2型糖尿病患者血糖控制和临床疗效[J]. 昆明医科大学学报, 2020, 41(4):111-116.
[18]	刘雷蕾, 马淑然. 基于肠道菌群介导的炎性反应研究黄芪多糖对结肠炎相关癌症的作用[J]. 世界中医药, 2021, 16(2):226-237.
[19]	黄东泉, 郑文霞, 谢惠芳, 等. 帕金森病患者肠道嗜黏蛋白阿克曼菌各亚型丰度的变化及其临床价值[J]. 实用医学杂志, 2020, 36(12):1673-1678.
[20]	陆玮, 肖乾, 胡烨婷, 等. 微生物与结直肠癌的发病机制、早期诊断和治疗的研究进展[J]. 肿瘤防治研究, 2020, 47(12):909-914.
[21]	刘素萍, 蒋青青, 金晶, 等. 中医药调节溃疡性结肠炎肠道菌群研究概况[J]. 中华中医药学刊, 2021, 39(3):208-212.
[22]	李中玉. 晚期早发性结直肠癌与晚发性结直肠癌的回顾性研究[D]. 北京: 中国中医科学院, 2020.
[23]	归明彬, 王雅楠, 邹敏, 等. 结直肠癌瘀毒内阻证与气血两虚证患者肠道菌群差异性研究[J]. 中国微生态学杂志, 2023, 35(7):797-801.
[24]	龚红霞, 苏韫, 刘永琦. 胃肠道菌群与胃癌的关系及中医药的作用研究[J]. 肿瘤代谢与营养电子杂志, 2018, 5(1):26-29.
[25]	王婷, 周利红, 李琦, 等. 肠道菌群对肿瘤的影响及中医药调节作用研究进展[J]. 中华中医药学刊, 2019, 37(11):2704-2707.

症状	评分标准	得分
刺痛、痛有定处、拒按	正常	0分
	偶尔发生	1分
	按之痛甚，服药一般可缓解	2分
	持续疼痛，需服止痛药才可缓解	3分
出血	无出血	0分
	少量出血	1分
	中量出血	2分
	多个部位或重创出血	3分
肢体麻木或偏瘫	正常	0分
	偶有麻木，可自行缓解	1分
	自觉肢体麻木，不能缓解，轻度偏瘫	2分
	肢体麻木，偏瘫或双侧瘫痪	3分
乏力	无	0分
	活动后倦怠乏力	1分
	未活动后倦怠乏力	2分
	倦怠乏力显著增加	3分
抑郁焦虑	无情绪障碍	0分
	偶有抑郁焦虑发作，可自行平息	1分
	时有抑郁焦虑发作，劝慰可止	2分
	经常发作，须强行制止或服药治疗	3分
总分		100分

症候	对照组		治疗组
症候	治疗前	治疗后	治疗前	治疗后
刺痛、痛有定处、拒按	1.00±0.78	1.52±0.99	1.72±0.86	1.36±0.86^2）
出血	1.60±0.81	1.40±0.76	1.50±0.71	1.40±0.95
抑郁焦虑	1.28±0.76	1.44±0.81	1.22±0.82	0.82±0.75^1）2）
乏力	1.12±0.78	1.28±1.05	1.12±0.80	0.62±0.70^1）2）
肢体麻木或偏瘫	1.40±0.81	1.22±0.95	1.16±0.82	0.73±0.70

分类	治疗组	对照组	t	P
门	8.67±2.13	8.4±1.41	0.405	0.688
纲	15.67±3.24	16.13±2.59	0.436	0.667
目	23.47±5.59	22.80±5.33	0.334	0.741
科	38.87±7.90	38.33±7.67	0.188	0.853
属	51.47±8.75	54.6±10.11	0.908	0.372
种	43±11.21	45.67±7.95	0.459	0.459